NASDAQ:SRPT - Sarepta Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $119.25
  • Forecasted Upside: 57.45 %
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.03 (0.04%)

This chart shows the closing price for SRPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sarepta Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SRPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRPT

Analyst Price Target is $119.25
▲ +57.45% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $119.25, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 57.45% upside from the last price of $75.74.

This chart shows the closing price for SRPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 13 contributing investment analysts is to buy stock in Sarepta Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 16 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 14 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 15 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/24/2022Cantor FitzgeraldLower Price TargetOverweight$140.00 ➝ $128.00Low
6/24/2022Credit Suisse GroupLower Price TargetNeutral$95.00 ➝ $90.00Low
5/24/2022The Goldman Sachs GroupLower Price TargetBuy$181.00 ➝ $155.00Medium
5/19/2022Morgan StanleyLower Price TargetEqual Weight$77.00 ➝ $74.00Low
4/12/2022Morgan StanleyLower Price TargetEqual Weight$80.00 ➝ $77.00Low
3/7/2022Morgan StanleyBoost Price TargetEqual Weight$71.00 ➝ $80.00High
3/2/2022BarclaysLower Price Target$125.00 ➝ $104.00Medium
3/2/2022Royal Bank of CanadaBoost Price TargetOutperform$145.00 ➝ $150.00High
2/1/2022Morgan StanleyLower Price TargetEqual Weight$92.00 ➝ $71.00Medium
1/18/2022Morgan StanleyBoost Price TargetEqual Weight$90.00 ➝ $92.00Low
1/11/2022Needham & Company LLCReiterated RatingBuy$150.00Medium
1/5/2022Needham & Company LLCLower Price TargetBuy$157.00 ➝ $150.00High
12/9/2021OppenheimerUpgradeMarket Perform ➝ Outperform$125.00Medium
11/5/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$88.00 ➝ $130.00Medium
11/4/2021Cantor FitzgeraldBoost Price TargetOverweight$128.00 ➝ $140.00High
11/4/2021Royal Bank of CanadaLower Price TargetOutperform$148.00 ➝ $145.00High
11/4/2021Needham & Company LLCLower Price TargetBuy$166.00 ➝ $157.00High
10/15/2021Berenberg BankReiterated RatingHold$90.00High
10/12/2021Credit Suisse GroupBoost Price TargetNeutral$75.00 ➝ $100.00High
10/12/2021SVB LeerinkReiterated RatingBuyHigh
10/12/2021Needham & Company LLCReiterated RatingBuyHigh
10/12/2021BTIG ResearchBoost Price TargetBuy$110.00 ➝ $125.00High
10/7/2021Robert W. BairdInitiated CoverageBuy$110.00Medium
9/15/2021GuggenheimUpgradeNeutral ➝ BuyHigh
8/16/2021Morgan StanleyLower Price TargetEqual Weight$93.00 ➝ $90.00High
8/5/2021Credit Suisse GroupBoost Price TargetNeutral$72.00 ➝ $75.00High
8/5/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$92.00 ➝ $87.00High
7/1/2021Berenberg BankInitiated CoverageHold$85.00Medium
6/14/2021BTIG ResearchInitiated CoverageBuy$110.00High
5/3/2021Needham & Company LLCInitiated CoverageBuy$166.00High
4/19/2021Morgan StanleyLower Price TargetEqual Weight$95.00 ➝ $93.00Low
4/16/2021William BlairReiterated RatingBuyLow
3/21/2021SVB LeerinkReiterated RatingBuyLow
3/2/2021Royal Bank of CanadaLower Price TargetOutperform$143.00 ➝ $132.00High
3/2/2021Needham & Company LLCReiterated RatingBuy$166.00High
3/2/2021SVB LeerinkBoost Price TargetOutperform$125.00 ➝ $126.00High
3/2/2021Piper SandlerLower Price TargetNeutral$140.00 ➝ $130.00High
2/26/2021MizuhoBoost Price TargetBuy$158.00 ➝ $160.00High
1/12/2021Smith Barney CitigroupDowngradeBuy ➝ NeutralHigh
1/11/2021UBS GroupDowngradeBuy ➝ NeutralHigh
1/8/2021OppenheimerReiterated RatingHold ➝ NeutralHigh
1/8/2021Credit Suisse GroupLower Price TargetNeutral$156.00 ➝ $73.00N/A
1/8/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight$96.00N/A
1/8/2021Robert W. BairdLower Price TargetOutperform$223.00 ➝ $110.00N/A
1/8/2021CowenLower Price TargetOutperform$213.00 ➝ $114.00N/A
1/8/2021Needham & Company LLCLower Price TargetBuy$182.00 ➝ $166.00N/A
1/8/2021BarclaysLower Price TargetPositive ➝ Overweight$192.00 ➝ $125.00N/A
1/8/2021Cantor FitzgeraldLower Price TargetOverweight$217.00 ➝ $128.00N/A
1/8/2021Royal Bank of CanadaLower Price TargetOutperform$200.00 ➝ $143.00N/A
1/8/2021MizuhoLower Price TargetBuy$204.00 ➝ $158.00N/A
1/8/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$182.00 ➝ $95.00N/A
1/8/2021Raymond JamesDowngradeOutperform ➝ Market PerformN/A
1/8/2021SVB LeerinkLower Price TargetOutperform$197.00 ➝ $125.00N/A
1/4/2021Piper SandlerBoost Price TargetOverweight$200.00 ➝ $240.00N/A
12/14/2020Smith Barney CitigroupBoost Price Target$190.00 ➝ $215.00Low
12/14/2020Credit Suisse GroupLower Price TargetNeutral$162.00 ➝ $156.00Medium
12/8/2020MizuhoBoost Price TargetBuy$192.00 ➝ $204.00High
11/11/2020Berenberg BankInitiated CoverageHold$140.00Medium
11/6/2020Credit Suisse GroupLower Price TargetNeutral$167.00 ➝ $162.00High
11/6/2020SVB LeerinkLower Price TargetOutperform$214.00 ➝ $197.00High
10/28/2020UBS GroupInitiated CoverageBuy$212.00Low
10/11/2020Royal Bank of CanadaReiterated RatingBuyLow
9/15/2020CitigroupBoost Price TargetBuy$177.00 ➝ $190.00Medium
8/31/2020HC WainwrightLower Price TargetBuy$260.00 ➝ $221.00Low
8/24/2020Raymond JamesInitiated CoverageOutperform$200.00High
8/21/2020Bank of AmericaLower Price TargetBuy$190.00 ➝ $189.00Medium
8/20/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral$185.00 ➝ $167.00High
8/10/2020Morgan StanleyBoost Price TargetOverweight$172.00 ➝ $182.00Low
8/4/2020Piper SandlerLower Price TargetOverweight$206.00 ➝ $200.00Low
8/3/2020Credit Suisse GroupReiterated RatingBuyLow
6/22/2020JPMorgan Chase & Co.Boost Price TargetOverweight$160.00 ➝ $190.00Low
6/16/2020HC WainwrightReiterated RatingBuy$260.00Medium
6/10/2020Bank of AmericaReiterated RatingBuy$180.00High
6/8/2020HC WainwrightReiterated RatingBuy$260.00High
6/8/2020Robert W. BairdReiterated RatingBuy$192.00High
5/17/2020NomuraReiterated RatingBuy$230.00High
5/15/2020JPMorgan Chase & Co.Reiterated RatingBuyHigh
5/15/2020Robert W. BairdReiterated RatingBuy$192.00High
5/15/2020HC WainwrightReiterated RatingBuy$260.00High
5/7/2020Needham & Company LLCInitiated CoverageBuy$182.00High
5/7/2020Credit Suisse GroupReiterated RatingBuy$185.00High
5/7/2020OppenheimerReiterated RatingHoldHigh
5/6/2020Royal Bank of CanadaReiterated RatingBuy$182.00Low
4/30/2020MizuhoReiterated RatingBuy$183.00Low
4/15/2020Morgan StanleyLower Price TargetOverweight$173.00 ➝ $172.00Low
3/30/2020MizuhoInitiated CoverageBuy$183.00High
2/28/2020JPMorgan Chase & Co.Lower Price TargetOverweight$172.00 ➝ $160.00High
2/27/2020Cantor FitzgeraldReiterated RatingOverweight$211.00 ➝ $217.00High
2/27/2020JMP SecuritiesLower Price TargetOutperform$280.00 ➝ $217.00High
2/25/2020Nomura SecuritiesReiterated RatingBuy$230.00High
1/23/2020SVB LeerinkReiterated RatingBuy$216.00Low
1/14/2020Credit Suisse GroupReiterated RatingBuy$185.00Low
1/14/2020CowenReiterated RatingBuy$213.00High
1/7/2020Bank of AmericaReiterated RatingBuy$187.00High
12/30/2019OppenheimerReiterated RatingHoldLow
12/26/2019CitigroupReiterated RatingBuy$177.00Low
12/25/2019Nomura SecuritiesReiterated RatingBuy$230.00Low
12/24/2019The Goldman Sachs GroupReiterated RatingBuy$180.00Low
12/24/2019Morgan StanleyBoost Price TargetOverweight$160.00 ➝ $173.00Low
12/24/2019Credit Suisse GroupReiterated RatingOverweight ➝ Outperform$190.00 ➝ $185.00Low
12/23/2019Piper Jaffray CompaniesReiterated RatingBuy$210.00N/A
12/23/2019Royal Bank of CanadaLower Price TargetOutperform$215.00 ➝ $200.00Medium
12/20/2019Robert W. BairdBoost Price TargetOutperform$181.00 ➝ $192.00Low
12/18/2019Nomura SecuritiesReiterated RatingBuy$230.00Low
12/17/2019CitigroupBoost Price TargetBuy$167.00 ➝ $177.00Low
12/15/2019CowenInitiated CoverageBuy$213.00Medium
12/15/2019BarclaysReiterated RatingBuy$202.00Medium
12/13/2019HC WainwrightBoost Price Target$160.00 ➝ $260.00Low
12/13/2019Cantor FitzgeraldBoost Price TargetOverweight$175.00 ➝ $211.00High
12/13/2019SVB LeerinkReiterated RatingOutperform$186.00 ➝ $216.00Medium
12/13/2019Piper Jaffray CompaniesReiterated RatingBuy$185.00 ➝ $210.00High
12/13/2019Credit Suisse GroupBoost Price TargetOutperform$185.00 ➝ $190.00High
12/13/2019Janney Montgomery ScottBoost Price TargetBuy$160.00 ➝ $175.00High
12/13/2019Royal Bank of CanadaReiterated RatingOutperform$215.00High
11/18/2019CitigroupLower Price TargetBuy ➝ Positive$180.00 ➝ $167.00Low
11/8/2019Credit Suisse GroupLower Price TargetOutperform$201.00 ➝ $185.00High
11/1/2019GuggenheimInitiated CoverageBuy$183.00High
10/11/2019Morgan StanleyLower Price TargetOverweight$220.00 ➝ $160.00Low
10/8/2019OppenheimerReiterated RatingHoldLow
9/27/2019Piper Jaffray CompaniesSet Price TargetBuy$185.00Low
9/27/2019CitigroupLower Price TargetBuy$185.00 ➝ $180.00Medium
9/24/2019Royal Bank of CanadaSet Price TargetBuy$204.00High
9/13/2019HC WainwrightSet Price TargetBuy$160.00Low
8/21/2019Needham & Company LLCLower Price TargetBuy$196.00 ➝ $170.00Low
8/20/2019Royal Bank of CanadaLower Price TargetOutperform$204.00Low
8/20/2019Cantor FitzgeraldLower Price TargetOverweight$231.00 ➝ $175.00Low
8/20/2019Robert W. BairdLower Price TargetOutperform$202.00 ➝ $181.00High
8/20/2019Bank of AmericaLower Price TargetBuy$200.00 ➝ $189.00High
8/20/2019Credit Suisse GroupLower Price TargetOutperform$207.00 ➝ $201.00High
8/20/2019Janney Montgomery ScottLower Price TargetBuy$200.00 ➝ $175.00High
8/20/2019HC WainwrightReiterated RatingBuy$160.00 ➝ $267.00High
8/20/2019Piper Jaffray CompaniesLower Price TargetOverweight$208.00 ➝ $185.00High
8/9/2019William BlairReiterated RatingBuyLow
8/8/2019Evercore ISIReiterated RatingBuy$200.00High
7/9/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$165.00 ➝ $220.00Medium
7/1/2019Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$188.00 ➝ $220.00Low
6/17/2019HC WainwrightSet Price TargetBuy$267.00Low
5/16/2019CitigroupLower Price TargetBuy$201.00 ➝ $190.00Medium
5/14/2019Morgan StanleyLower Price TargetOverweight$169.00 ➝ $165.00Medium
5/9/2019Royal Bank of CanadaLower Price TargetOutperform$191.00 ➝ $188.00High
4/17/2019BTIG ResearchSet Price TargetBuy$190.00High
4/11/2019Evercore ISIInitiated CoverageOutperform$175.00High
3/31/2019CowenReiterated RatingBuy$213.00Low
3/28/2019Piper Jaffray CompaniesBoost Price TargetOverweight$200.00 ➝ $208.00Low
3/12/2019BMO Capital MarketsInitiated CoverageOutperformLow
3/11/2019Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$189.00 ➝ $207.00Low
3/5/2019SVB LeerinkReiterated RatingOutperformLow
3/4/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$161.00 ➝ $169.00Low
3/1/2019CitigroupBoost Price TargetBuy ➝ Buy$188.00 ➝ $201.00Low
2/28/2019Nomura SecuritiesBoost Price TargetBuy ➝ Buy$205.00 ➝ $230.00Low
2/28/2019Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$217.00 ➝ $231.00High
2/27/2019JMP SecuritiesReiterated RatingBuy$270.00High
2/22/2019Cantor FitzgeraldReiterated RatingBuyHigh
2/5/2019BTIG ResearchSet Price TargetBuy$190.00Low
1/30/2019Piper Jaffray CompaniesBoost Price TargetOverweight$168.00 ➝ $200.00High
1/17/2019Royal Bank of CanadaReiterated RatingOutperform$164.00Low
1/8/2019Janney Montgomery ScottSet Price TargetBuy$200.00Medium
1/4/2019HC WainwrightSet Price TargetBuy$267.00High
12/28/2018BTIG ResearchSet Price TargetBuy$190.00Medium
12/10/2018HC WainwrightSet Price TargetBuy$267.00Low
11/26/2018Cantor FitzgeraldReiterated RatingBuy$217.00High
11/6/2018CitigroupBoost Price TargetBuy ➝ Buy$174.00 ➝ $188.00Medium
10/26/2018Piper Jaffray CompaniesLower Price TargetOverweight$189.00 ➝ $168.00Low
10/12/2018Sanford C. BernsteinInitiated CoverageOutperform$170.00High
10/4/2018Credit Suisse GroupBoost Price Target$178.00 ➝ $189.00High
10/4/2018Piper Jaffray CompaniesReiterated RatingOverweight$189.00High
10/1/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$217.00High
9/26/2018Royal Bank of CanadaReiterated RatingOutperform$187.00 ➝ $200.00Medium
9/24/2018BTIG ResearchSet Price TargetBuy$190.00Low
9/24/2018Needham & Company LLCLower Price TargetBuy$196.00Low
9/21/2018HC WainwrightReiterated RatingBuy$267.00High
9/14/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$199.00Low
9/6/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$178.00Medium
9/4/2018HC WainwrightSet Price TargetBuy$267.00High
8/14/2018CitigroupInitiated CoverageBuyMedium
8/9/2018CowenReiterated RatingBuy$178.00High
8/9/2018HC WainwrightSet Price TargetBuy$267.00High
8/1/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$163.00Low
7/18/2018HC WainwrightSet Price TargetBuy$267.00Medium
6/25/2018JMP SecuritiesBoost Price TargetOutperform$275.00Low
6/22/2018SunTrust BanksBoost Price TargetBuy$176.00High
6/21/2018Nomura SecuritiesBoost Price TargetBuy ➝ Buy$131.00 ➝ $205.00Medium
6/21/2018Robert W. BairdReiterated RatingOutperform ➝ Outperform$120.00 ➝ $202.00Medium
6/20/2018WBB SecuritiesReiterated RatingBuyLow
6/20/2018Royal Bank of CanadaBoost Price TargetOutperform$189.00Medium
6/20/2018Needham & Company LLCBoost Price TargetBuy$109.00 ➝ $204.00Medium
6/20/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$91.00 ➝ $163.00High
6/20/2018CowenReiterated RatingOutperform$178.00High
6/20/2018SVB LeerinkReiterated RatingOutperform ➝ OutperformHigh
6/20/2018BarclaysReiterated RatingOverweight$180.00High
6/20/2018Piper Jaffray CompaniesReiterated RatingOverweight$168.00High
6/19/2018William BlairReiterated RatingBuyHigh
6/19/2018JPMorgan Chase & Co.Reiterated RatingOverweightHigh
6/19/2018HC WainwrightBoost Price TargetBuy$96.00 ➝ $267.00High
6/15/2018BTIG ResearchInitiated CoverageBuy$120.00High
6/11/2018HC WainwrightReiterated RatingBuy$96.00Low
5/18/2018The Goldman Sachs GroupBoost Price TargetBuy$84.00 ➝ $127.00Low
5/15/2018SVB LeerinkBoost Price TargetHold ➝ Outperform$88.00 ➝ $121.00Low
5/11/2018BarclaysUpgradeEqual Weight ➝ Overweight$55.00 ➝ $107.00Low
5/7/2018Needham & Company LLCBoost Price TargetIn-Line ➝ Buy$75.00 ➝ $109.00Low
5/4/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$87.00 ➝ $91.00High
5/4/2018Credit Suisse GroupSet Price TargetOutperform ➝ Buy$100.00 ➝ $92.00High
5/4/2018Nomura SecuritiesBoost Price TargetBuy$131.00High
5/4/2018Royal Bank of CanadaBoost Price TargetOutperform ➝ Positive$98.00High
5/4/2018JMP SecuritiesReiterated RatingOutperform$95.00 ➝ $90.00High
5/4/2018HC WainwrightSet Price TargetBuy ➝ Buy$90.00 ➝ $96.00High
5/4/2018OppenheimerDowngradeOutperform ➝ Market PerformHigh
5/4/2018UBS GroupDowngradeOutperform ➝ Market PerformHigh
4/23/2018HC WainwrightReiterated RatingBuy$92.00High
4/5/2018Credit Suisse GroupSet Price TargetBuy$100.00Medium
3/21/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$64.00 ➝ $87.00Medium
3/16/2018SunTrust BanksBoost Price TargetBuy$95.00Medium
3/14/2018Royal Bank of CanadaReiterated RatingBuy$91.00Medium
3/14/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$75.00 ➝ $95.00Low
3/13/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$81.00 ➝ $100.00Low
3/13/2018SVB LeerinkReiterated RatingOutperform ➝ Positive$79.00 ➝ $92.00Medium
3/12/2018Credit Suisse GroupReiterated RatingHold$81.00High
3/12/2018HC WainwrightBoost Price TargetBuy ➝ Buy$75.00 ➝ $92.00High
3/12/2018Piper Jaffray CompaniesReiterated RatingOverweight$83.00 ➝ $76.12High
3/8/2018SunTrust BanksBoost Price TargetBuy$76.00Medium
3/6/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $64.00Low
3/2/2018Credit Suisse GroupSet Price TargetBuy$81.00Low
3/2/2018Nomura SecuritiesBoost Price TargetBuy$96.00High
3/2/2018HC WainwrightSet Price TargetBuy$75.00High
3/2/2018Piper Jaffray CompaniesReiterated RatingOverweightHigh
2/21/2018JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$63.00 ➝ $75.00Low
2/12/2018HC WainwrightSet Price TargetBuy$75.00High
2/5/2018William BlairReiterated RatingOutperformHigh
1/23/2018BarclaysReiterated RatingHold$55.00Low
1/22/2018Royal Bank of CanadaInitiated CoverageOutperform ➝ OutperformHigh
1/19/2018SVB LeerinkReiterated RatingOutperform$77.00Low
1/9/2018HC WainwrightReiterated RatingBuy$75.00Low
1/3/2018Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$75.00Medium
1/3/2018HC WainwrightSet Price TargetBuy$75.00Low
12/27/2017OppenheimerReiterated RatingBuy$76.00Low
12/27/2017UBS GroupReiterated RatingOutperform$76.00 ➝ $56.51Low
12/1/2017HC WainwrightInitiated CoverageBuy ➝ Buy$75.00High
10/27/2017Needham & Company LLCReiterated RatingBuyN/A
10/26/2017BarclaysBoost Price TargetEqual Weight$46.00 ➝ $49.00N/A
10/26/2017Piper Jaffray CompaniesReiterated RatingOverweightN/A
10/17/2017Robert W. BairdReiterated RatingBuy$101.00N/A
10/16/2017OppenheimerReiterated RatingBuy$76.00N/A
10/6/2017The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$71.00N/A
10/3/2017Royal Bank of CanadaReiterated RatingBuy$64.00Low
10/2/2017William BlairReiterated RatingOutperformLow
10/2/2017Nomura InstinetReiterated RatingBuy$84.00Low
10/2/2017Credit Suisse GroupReiterated RatingOutperform$81.00Low
10/2/2017Robert W. BairdReiterated RatingOutperform$101.00High
10/2/2017Morgan StanleyUpgradeEqual Weight ➝ Overweight$60.00High
9/30/2017SVB LeerinkReiterated RatingOutperform$66.00High
9/25/2017OppenheimerReiterated RatingBuyLow
9/25/2017JPMorgan Chase & Co.Reiterated RatingHoldLow
9/15/2017Royal Bank of CanadaInitiated CoveragePositiveLow
9/14/2017CowenReiterated RatingOutperform$69.00Medium
9/7/2017SunTrust BanksReiterated RatingBuy$56.00High
9/7/2017William BlairReiterated RatingOutperformHigh
9/7/2017Piper Jaffray CompaniesReiterated RatingOverweight$50.00 ➝ $55.00High
9/7/2017OppenheimerReiterated RatingBuy$76.00Low
9/7/2017Credit Suisse GroupBoost Price TargetOutperform$5.65 ➝ $81.00High
9/6/2017BarclaysInitiated CoverageEqual Weight$46.00Medium
9/6/2017Needham & Company LLCReiterated RatingBuy$75.00Low
9/6/2017Robert W. BairdReiterated RatingOutperform$101.00Low
9/5/2017Nomura SecuritiesReiterated RatingBuy$84.00Low
7/27/2017William BlairReiterated RatingOutperformLow
7/24/2017Janney Montgomery ScottBoost Price TargetBuy ➝ Fair Value$65.00 ➝ $73.00High
7/21/2017Robert W. BairdReiterated RatingOutperform$102.00 ➝ $96.00Low
7/20/2017Morgan StanleyReiterated RatingEqual Weight$31.00 ➝ $33.00High
7/20/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $64.00High
7/20/2017CowenReiterated RatingOutperform$62.00 ➝ $69.00High
7/20/2017SunTrust BanksReiterated RatingBuyHigh
7/20/2017Piper Jaffray CompaniesReiterated RatingOverweight$50.00High
7/18/2017Credit Suisse GroupSet Price TargetBuy$64.00High
7/18/2017SVB LeerinkReiterated RatingBuy$52.00 ➝ $60.00Low
7/12/2017Robert W. BairdReiterated RatingOutperform$102.00Low
(Data available from 7/6/2017 forward)

News Sentiment Rating

0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
  • 6 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Current Sentiment

  • 1 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Sarepta Therapeutics logo
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $75.74
Low: $73.07
High: $76.00

50 Day Range

MA: $70.66
Low: $62.69
High: $77.07

52 Week Range

Now: $75.74
Low: $61.28
High: $101.24


1,287,868 shs

Average Volume

721,869 shs

Market Capitalization

$6.63 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Sarepta Therapeutics?

The following sell-side analysts have issued stock ratings on Sarepta Therapeutics in the last year: Barclays PLC, Berenberg Bank, BTIG Research, Cantor Fitzgerald, Credit Suisse Group AG, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Robert W. Baird, Royal Bank of Canada,, SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for SRPT.

What is the current price target for Sarepta Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Sarepta Therapeutics in the last year. Their average twelve-month price target is $119.25, suggesting a possible upside of 57.4%.
View the latest price targets for SRPT.

What is the current consensus analyst rating for Sarepta Therapeutics?

Sarepta Therapeutics currently has 3 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SRPT will outperform the market and that investors should add to their positions of Sarepta Therapeutics.
View the latest ratings for SRPT.

How do I contact Sarepta Therapeutics' investor relations team?

Sarepta Therapeutics' physical mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is (857) 242-4000 and its investor relations email address is [email protected] The official website for Sarepta Therapeutics is Learn More about contacing Sarepta Therapeutics investor relations.